Yusuke Narita
Overview
Explore the profile of Yusuke Narita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Imaoka T, Antoku N, Narita Y, Nishiyama K, Takada K, Saito S, et al.
Chem Sci
. 2024 Sep;
PMID: 39246354
While the utility of supported metal and alloy clusters as catalytic materials is widely recognized, their precise synthesis remains a challenge. Here, we demonstrate the precise synthesis of these clusters...
2.
Wang X, Deliu N, Narita Y, Chakraborty B
Biometrics
. 2024 Feb;
80(1).
PMID: 38364800
Dynamic treatment regimes (DTRs) are sequences of decision rules that recommend treatments based on patients' time-varying clinical conditions. The sequential, multiple assignment, randomized trial (SMART) is an experimental design that...
3.
Kosai K, Kaku N, Horie M, Kodama H, Akamatsu N, Narita Y, et al.
Virol J
. 2022 Nov;
19(1):188.
PMID: 36384638
Introduction: We investigated the performance of the cobas® 6800 system and cobas SARS-CoV-2 & Influenza A/B, a fully automated molecular testing system for influenza viruses and severe acute respiratory syndrome...
4.
Narita Y, Funatogawa T, Mii K, Adachi H, Tamura A, Yamakido S
Mod Rheumatol
. 2022 Jun;
33(3):525-532.
PMID: 35652700
Objectives: Limited information is available on the use of biologics in patients with systemic sclerosis (SSc) or SSc-associated interstitial lung disease (SSc-ILD) in Japan. The types of biologics, treatment duration,...
5.
Narita Y, Yoshimoto T, Namai T, Asakawa T, Kawakami S, Gower-Page C, et al.
JCO Clin Cancer Inform
. 2022 Jun;
6:e2200022.
PMID: 35649212
Purpose: We compared overall survival (OS) in patients with human epidermal growth factor receptor 2 ()-amplified, treatment-refractory metastatic colorectal cancer (mCRC) receiving pertuzumab plus trastuzumab (PER-HER) in the phase IIa...
6.
Funatogawa T, Narita Y, Tamura A, Mii K, Sugitani Y, Uchida T
Clin Exp Nephrol
. 2022 May;
26(10):1005-1013.
PMID: 35579722
Background: Current treatment for frequently relapsing, steroid-dependent, or steroid-resistant nephrotic syndrome focuses on immunosuppressive therapies. Although the clinical guideline suggests the use of mycophenolate mofetil (MMF), limited information is available...
7.
Funatogawa T, Narita Y, Tamura A, Mii K, Sugitani Y, Uchida T
Mod Rheumatol
. 2021 Dec;
32(4):755-760.
PMID: 34850080
Objectives: Limited information is available on patients with systemic sclerosis (SSc) or SSc-associated interstitial lung disease (SSc-ILD) receiving mycophenolate mofetil (MMF) in Japan. The dose, treatment duration, and patient characteristics...
8.
Ishihara K, Narita Y, Teramura Y, Fukazawa K
ACS Biomater Sci Eng
. 2021 Oct;
7(11):5107-5117.
PMID: 34677934
Cationic magnetic hydrogel microparticles with high retention on cell surfaces were prepared using a two-step procedure. Using these magnetic hydrogel microparticles, cells were clustered with each other, and cell aggregates...
9.
Kaku N, Kodama H, Akamatsu N, Ota K, Kosai K, Morinaga Y, et al.
J Infect Chemother
. 2021 Jan;
27(6):820-825.
PMID: 33509674
Introduction: Digital immunoassays (DIAs) and molecular point-of-care (POC) tests for influenza were recently developed. We aimed to evaluate and compare the positive rate with molecular POC tests and DIAs in...
10.
Narita Y
Proc Natl Acad Sci U S A
. 2021 Jan;
118(1).
PMID: 33443151
Randomized controlled trials (RCTs) enroll hundreds of millions of subjects and involve many human lives. To improve subjects' welfare, I propose a design of RCTs that I call Experiment-as-Market (EXAM)....